Cargando…

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex

The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. The AR represents a near-universal driver and therapeutic vulnerability in metastatic prostate cancer, and targeting AR has a remarkable therapeutic index. Though most approaches directed toward AR focus...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyquist, Michael D., Coleman, Ilsa M., Lucas, Jared M., Li, Dapei, Hanratty, Brian, Meade, Hannah, Mostaghel, Elahe A., Plymate, Stephen R., Corey, Eva, Haffner, Michael C., Nelson, Peter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472100/
https://www.ncbi.nlm.nih.gov/pubmed/37352376
http://dx.doi.org/10.1158/0008-5472.CAN-22-2613
_version_ 1785100002058567680
author Nyquist, Michael D.
Coleman, Ilsa M.
Lucas, Jared M.
Li, Dapei
Hanratty, Brian
Meade, Hannah
Mostaghel, Elahe A.
Plymate, Stephen R.
Corey, Eva
Haffner, Michael C.
Nelson, Peter S.
author_facet Nyquist, Michael D.
Coleman, Ilsa M.
Lucas, Jared M.
Li, Dapei
Hanratty, Brian
Meade, Hannah
Mostaghel, Elahe A.
Plymate, Stephen R.
Corey, Eva
Haffner, Michael C.
Nelson, Peter S.
author_sort Nyquist, Michael D.
collection PubMed
description The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. The AR represents a near-universal driver and therapeutic vulnerability in metastatic prostate cancer, and targeting AR has a remarkable therapeutic index. Though most approaches directed toward AR focus on inhibiting AR signaling, laboratory and now clinical data have shown that high dose, supraphysiological androgen treatment (SPA) results in growth repression and improved outcomes in subsets of patients with prostate cancer. A better understanding of the mechanisms contributing to SPA response and resistance could help guide patient selection and combination therapies to improve efficacy. To characterize SPA signaling, we integrated metrics of gene expression changes induced by SPA together with cistrome data and protein-interactomes. These analyses indicated that the dimerization partner, RB-like, E2F, and multivulval class B (DREAM) complex mediates growth repression and downregulation of E2F targets in response to SPA. Notably, prostate cancers with complete genomic loss of RB1 responded to SPA treatment, whereas loss of DREAM complex components such as RBL1/2 promoted resistance. Overexpression of MYC resulted in complete resistance to SPA and attenuated the SPA/AR-mediated repression of E2F target genes. These findings support a model of SPA-mediated growth repression that relies on the negative regulation of MYC by AR leading to repression of E2F1 signaling via the DREAM complex. The integrity of MYC signaling and DREAM complex assembly may consequently serve as determinants of SPA responses and as pathways mediating SPA resistance. SIGNIFICANCE: Determining the molecular pathways by which supraphysiological androgens promote growth arrest and treatment responses in prostate cancer provides opportunities for biomarker-selected clinical trials and the development of strategies to augment responses.
format Online
Article
Text
id pubmed-10472100
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-104721002023-09-02 Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex Nyquist, Michael D. Coleman, Ilsa M. Lucas, Jared M. Li, Dapei Hanratty, Brian Meade, Hannah Mostaghel, Elahe A. Plymate, Stephen R. Corey, Eva Haffner, Michael C. Nelson, Peter S. Cancer Res Translational Cancer Biology The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. The AR represents a near-universal driver and therapeutic vulnerability in metastatic prostate cancer, and targeting AR has a remarkable therapeutic index. Though most approaches directed toward AR focus on inhibiting AR signaling, laboratory and now clinical data have shown that high dose, supraphysiological androgen treatment (SPA) results in growth repression and improved outcomes in subsets of patients with prostate cancer. A better understanding of the mechanisms contributing to SPA response and resistance could help guide patient selection and combination therapies to improve efficacy. To characterize SPA signaling, we integrated metrics of gene expression changes induced by SPA together with cistrome data and protein-interactomes. These analyses indicated that the dimerization partner, RB-like, E2F, and multivulval class B (DREAM) complex mediates growth repression and downregulation of E2F targets in response to SPA. Notably, prostate cancers with complete genomic loss of RB1 responded to SPA treatment, whereas loss of DREAM complex components such as RBL1/2 promoted resistance. Overexpression of MYC resulted in complete resistance to SPA and attenuated the SPA/AR-mediated repression of E2F target genes. These findings support a model of SPA-mediated growth repression that relies on the negative regulation of MYC by AR leading to repression of E2F1 signaling via the DREAM complex. The integrity of MYC signaling and DREAM complex assembly may consequently serve as determinants of SPA responses and as pathways mediating SPA resistance. SIGNIFICANCE: Determining the molecular pathways by which supraphysiological androgens promote growth arrest and treatment responses in prostate cancer provides opportunities for biomarker-selected clinical trials and the development of strategies to augment responses. American Association for Cancer Research 2023-09-01 2023-06-23 /pmc/articles/PMC10472100/ /pubmed/37352376 http://dx.doi.org/10.1158/0008-5472.CAN-22-2613 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Translational Cancer Biology
Nyquist, Michael D.
Coleman, Ilsa M.
Lucas, Jared M.
Li, Dapei
Hanratty, Brian
Meade, Hannah
Mostaghel, Elahe A.
Plymate, Stephen R.
Corey, Eva
Haffner, Michael C.
Nelson, Peter S.
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
title Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
title_full Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
title_fullStr Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
title_full_unstemmed Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
title_short Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
title_sort supraphysiological androgens promote the tumor suppressive activity of the androgen receptor through cmyc repression and recruitment of the dream complex
topic Translational Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472100/
https://www.ncbi.nlm.nih.gov/pubmed/37352376
http://dx.doi.org/10.1158/0008-5472.CAN-22-2613
work_keys_str_mv AT nyquistmichaeld supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex
AT colemanilsam supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex
AT lucasjaredm supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex
AT lidapei supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex
AT hanrattybrian supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex
AT meadehannah supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex
AT mostaghelelahea supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex
AT plymatestephenr supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex
AT coreyeva supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex
AT haffnermichaelc supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex
AT nelsonpeters supraphysiologicalandrogenspromotethetumorsuppressiveactivityoftheandrogenreceptorthroughcmycrepressionandrecruitmentofthedreamcomplex